New Bids for Oxford GlycoSciences Expected | GenomeWeb

NEW YORK, March 31 - British biotech investors Sir Christopher Evans and Alan Goodman are considering a joint bid for Oxford GlycoSciences that would top the current offers by Celltech and Cambridge Antibody Technology, a source close to Evans told GenomeWeb today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.